Industry
Biotechnology
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Loading...
Open
0.24
Mkt cap
15M
Volume
209K
High
0.25
P/E Ratio
-0.43
52-wk high
0.62
Low
0.24
Div yield
N/A
52-wk low
0.21
Portfolio Pulse from Benzinga Newsdesk
August 20, 2024 | 12:32 pm
Portfolio Pulse from Benzinga Newsdesk
August 16, 2024 | 11:25 am
Portfolio Pulse from Benzinga Newsdesk
July 24, 2024 | 12:50 pm
Portfolio Pulse from Benzinga Newsdesk
May 31, 2024 | 12:33 pm
Portfolio Pulse from Benzinga Newsdesk
May 16, 2024 | 10:54 am
Portfolio Pulse from Benzinga Newsdesk
May 06, 2024 | 12:38 pm
Portfolio Pulse from Benzinga Newsdesk
April 10, 2024 | 12:22 pm
Portfolio Pulse from Benzinga Newsdesk
April 03, 2024 | 2:58 am
Portfolio Pulse from Benzinga Newsdesk
April 02, 2024 | 11:34 am
Portfolio Pulse from Benzinga Insights
April 02, 2024 | 10:25 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.